Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds: detection, notification, and early intervention. Infection in chronic wounds...
Bryan Campbell leads the Colorado Medical Society and started of his mission going back to the fundamental question of why CMS exists. How can...
Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in...
